SHUTTLE PHARMACEUTICALS HOLD (SHPH) Stock Price & Overview
NASDAQ:SHPH • US8256934014
Current stock price
The current stock price of SHPH is 1.05 USD. Today SHPH is up by 1.94%. In the past month the price increased by 58.3%. In the past year, price decreased by -85.26%.
SHPH Key Statistics
- Market Cap
- 5.87M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -12.88
- Dividend Yield
- N/A
SHPH Stock Performance
SHPH Stock Chart
SHPH Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to SHPH. When comparing the yearly performance of all stocks, SHPH is a bad performer in the overall market: 97.94% of all stocks are doing better.
SHPH Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to SHPH. The financial health of SHPH is average, but there are quite some concerns on its profitability.
SHPH Earnings
SHPH Forecast & Estimates
SHPH Groups
Sector & Classification
SHPH Financial Highlights
Over the last trailing twelve months SHPH reported a non-GAAP Earnings per Share(EPS) of -12.88. The EPS increased by 91.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -111.89% | ||
| ROE | -519.92% | ||
| Debt/Equity | 0 |
SHPH Ownership
SHPH Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.31 | 351.47B | ||
| AMGN | AMGEN INC | 14.9 | 185.95B | ||
| GILD | GILEAD SCIENCES INC | 14.45 | 161.855B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.87 | 109.449B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.88 | 79.456B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.2 | 40.768B | ||
| INSM | INSMED INC | N/A | 29.176B | ||
| NTRA | NATERA INC | N/A | 28.878B | ||
| BIIB | BIOGEN INC | 11.21 | 27.06B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 26.812B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.4 | 24.859B | ||
| MRNA | MODERNA INC | N/A | 20.119B | ||
| INCY | INCYTE CORP | 12.37 | 18.836B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SHPH
Company Profile
Shuttle Pharmaceuticals Holdings, Inc. is a clinical stage pharmaceutical company, which engages in the development of novel therapies for cancer. The company is headquartered in Gaithersburg, Maryland and currently employs 9 full-time employees. The company went IPO on 2022-08-31. Its product candidates include Ropidoxuridine, a Phase II, clinical-stage radiation sensitizer, a platform of HDAC inhibitors (SP-1-161, SP-2-225 and SP-1-303), and two preclinical, prostate cancer-oriented diagnostics assets: PC-RAD Test, a blood test to predict clinical response to radiation therapy and PSMA-B ligand for potential use as a theranostic agent. Ropidoxuridine (IPdR) is for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. SP-1-161 is a candidate lead of compounds demonstrating activation of the ATM gene product (mutated in Ataxia-Telangiectasia). SP-2-225 is a candidate lead of compounds demonstrating Class II (HDAC6) selective inhibition. SP-1-303 is a candidate Class I HDAC inhibitor with preferential efficacy against ER positive cancers.
Company Info
IPO: 2022-08-31
SHUTTLE PHARMACEUTICALS HOLD
401 Professional Drive, Suite 260
Gaithersburg MARYLAND US
Employees: 9
Phone: 12404034212
SHUTTLE PHARMACEUTICALS HOLD / SHPH FAQ
What does SHUTTLE PHARMACEUTICALS HOLD do?
Shuttle Pharmaceuticals Holdings, Inc. is a clinical stage pharmaceutical company, which engages in the development of novel therapies for cancer. The company is headquartered in Gaithersburg, Maryland and currently employs 9 full-time employees. The company went IPO on 2022-08-31. Its product candidates include Ropidoxuridine, a Phase II, clinical-stage radiation sensitizer, a platform of HDAC inhibitors (SP-1-161, SP-2-225 and SP-1-303), and two preclinical, prostate cancer-oriented diagnostics assets: PC-RAD Test, a blood test to predict clinical response to radiation therapy and PSMA-B ligand for potential use as a theranostic agent. Ropidoxuridine (IPdR) is for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. SP-1-161 is a candidate lead of compounds demonstrating activation of the ATM gene product (mutated in Ataxia-Telangiectasia). SP-2-225 is a candidate lead of compounds demonstrating Class II (HDAC6) selective inhibition. SP-1-303 is a candidate Class I HDAC inhibitor with preferential efficacy against ER positive cancers.
What is the current price of SHPH stock?
The current stock price of SHPH is 1.05 USD. The price increased by 1.94% in the last trading session.
Does SHPH stock pay dividends?
SHPH does not pay a dividend.
How is the ChartMill rating for SHUTTLE PHARMACEUTICALS HOLD?
SHPH has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the Price/Earnings (PE) ratio of SHUTTLE PHARMACEUTICALS HOLD (SHPH)?
SHUTTLE PHARMACEUTICALS HOLD (SHPH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-12.88).
What is the Short Interest ratio of SHUTTLE PHARMACEUTICALS HOLD (SHPH) stock?
The outstanding short interest for SHUTTLE PHARMACEUTICALS HOLD (SHPH) is 2.09% of its float.